文献速递衰弱、肌少症与跌倒老年慢病共病管理

多组学孟德尔随机化与单细胞分析识别骨肌减少症新治疗靶点

Multi-omics Mendelian randomization and single-cell analysis identify novel therapeutic targets for osteosarcopenia.
PubMed 文献 · J Gerontol A Biol Sci Med Sci · 2025-01-01

本研究采用多组学孟德尔随机化(MR)、基于汇总数据的MR(SMR)及共定位分析,结合单细胞RNA测序(scRNA-seq),从大规模全基因组关联研究(GWAS)的血浆转录组和蛋白质组数据中识别与骨肌减少症因果相关的治疗靶点。MGP、CTSS和SNUPN为保护因素,MMP16、ART4和PSMD9与风险增加相关;SMR和共定位分析进一步支持上述结果,组织与单细胞表达提示MGP和CTSS可能直接影响肌肉骨骼系统。

要点

  • MGP、CTSS、SNUPN为保护因素,MMP16、ART4、PSMD9与风险增加相关。
  • MGP和CTSS的单细胞表达提示其可能直接影响肌肉骨骼系统。

核心结论

  • ART4、MMP16和PSMD9可能是骨肌减少症的风险因素,而MGP、SNUPN和CTSS显示保护潜力。
  • 需进一步研究验证这些靶点并探究其在特定组织和细胞背景中的作用。

研究设计与样本

  • 采用转录组和蛋白质组范围的孟德尔随机化(MR)、基于汇总数据的MR(SMR)及共定位分析。
  • 分析大规模GWAS的血浆转录组和蛋白质组数据,并结合单细胞RNA测序(scRNA-seq)表达数据。
  • MR分析在eQTLgen、deCODE和Fenland数据集中鉴定出331个基因、20个和24个蛋白质与骨肌减少症特征因果相关。

主要发现

  • MGP、CTSS和SNUPN被识别为保护因素,MMP16、ART4和PSMD9与骨肌减少症风险增加相关。
  • SMR和共定位分析进一步支持上述验证结果。
  • 候选靶点的组织和单细胞表达提示MGP和CTSS可能直接影响肌肉骨骼系统,而其他靶点可能不直接作用。

临床怎么用

  • 本研究为骨肌减少症提供了候选治疗靶点,但尚未转化为临床干预推荐。
  • MGP、CTSS和SNUPN的保护潜力及ART4、MMP16和PSMD9的风险关联可供未来靶向治疗研究参考。

局限性

  • 研究结论基于遗传学关联分析,需进一步实验验证这些靶点。
  • 靶点在特定组织和细胞背景中的作用尚待探究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Osteosarcopenia, defined by the coexistence of osteoporosis and sarcopenia, presents a significant health challenge for aging populations. The purpose of current study was to identify potential therapeutic targets for osteosarcopenia using integrative analysis methods, including multi-omics Mendelian Randomization (MR) and single-cell RNA sequencing (scRNA-seq). METHODS: An integrative analysis using transcriptome, proteome wide MR, Summary-based MR (SMR), and colocalization analysis was performed. Data from large-scale genome-wide association studies (GWAS) of plasma transcriptome, proteome were analyzed. The expression data for these candidate targets across different tissues and cell types to further explore how they might contribute to the development of osteosarcopenia. RESULTS: The MR analysis identified 331 genes, 20 and 24 proteins in the eQTLgen, deCODE, and Fenland datasets that were causally associated with osteosarcopenia traits. Twelve causal targets were validated in at least two datasets, and the causal direction was generally consistent. Among these, MGP, CTSS, and SNUPN were recognized as protective factors, while MMP16, ART4, and PSMD9 were associated with an increased risk of osteosarcopenia. Validation was further supported by SMR and colocalization analyses. The tissue and single-cell expression of these candidate targets suggested that MGP and CTSS may directly influence the musculoskeletal system, while the others might not. CONCLUSIONS: Our findings suggest that ART4, MMP16, and PSMD9 may be risk factors for osteosarcopenia, whereas MGP, SNUPN, and CTSS show protective potential. Further investigations are needed to validate these targets and investigate their roles in specific tissues and cellular contexts, advancing osteosarcopenia management strategies.

来源:J Gerontol A Biol Sci Med Sci,查看原文。版权归原作者所有。

引用

  1. Yang J, Gong M, Zhou Y, et al. Multi-omics Mendelian randomization and single-cell analysis identify novel therapeutic targets for osteosarcopenia. J Gerontol A Biol Sci Med Sci. 2025. PMID: 41071635. doi:10.1093/gerona/glaf228

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。